Does Aetna Cover Semaglutide for Weight Loss? The 2026 Policy Breakdown and Your Real Options

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Aetna covers Ozempic (semaglutide 0.5-2 mg) for type 2 diabetes under most commercial and Medicare Advantage plans, but requires prior authorization and step therapy in 78% of plans
• Wegovy (semaglutide 2.4 mg) for weight loss is excluded from standard Aetna commercial plans unless the employer specifically purchases obesity coverage, which only 12-18% do as of 2026
• Aetna Medicare Advantage plans categorically exclude all weight-loss medications including Wegovy under the Medicare Part D statutory exclusion
• Compounded semaglutide falls outside insurance coverage entirely but costs $297-$399 per month through platforms like FormBlends, often less than brand-name copays after deductible

Direct answer (40-60 words)

Aetna covers semaglutide for FDA-approved diabetes treatment (Ozempic, Rybelsus) under most plans with prior authorization. Wegovy for weight loss is excluded from standard commercial plans and all Medicare Advantage plans. Coverage depends on your specific plan type, employer-purchased riders, and whether you meet clinical criteria. Most patients pay out-of-pocket or use compounded alternatives.

Table of contents

1. The coverage split: diabetes vs weight loss
2. Aetna commercial plan coverage for Ozempic (diabetes)
3. Why Wegovy is excluded from most Aetna plans
4. The employer rider exception: when weight-loss coverage exists
5. Aetna Medicare Advantage: the statutory exclusion problem
6. Prior authorization requirements and step therapy protocols
7. What most articles get wrong about "medical necessity"
8. The compounded semaglutide alternative
9. Cost comparison: brand-name with insurance vs compounded out-of-pocket
10. The FormBlends coverage decision framework
11. When to appeal a denial
12. FAQ

The coverage split: diabetes vs weight loss

Aetna, like all major U.S. insurers, draws a bright line between semaglutide for diabetes and semaglutide for weight loss. The same molecule, different FDA indication, completely different coverage.

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved for type 2 diabetes. Aetna covers it under the prescription drug benefit on most commercial and Medicare Advantage plans. Coverage requires prior authorization, and many plans impose step therapy (you must try metformin and at least one other diabetes medication first).

Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. Aetna excludes Wegovy from standard commercial plan formularies. It appears on the exclusion list alongside phentermine, orlistat, and other anti-obesity medications unless the employer purchases optional obesity coverage.

Rybelsus (oral semaglutide 3 mg, 7 mg, 14 mg) is FDA-approved for diabetes only. Aetna covers it on most plans with prior authorization, typically as a tier 3 or tier 4 specialty medication.

The coverage split exists because the Affordable Care Act mandates coverage for diabetes medications but does not mandate coverage for weight-loss medications. Insurers treat obesity pharmacotherapy as an optional benefit that employers can purchase separately.

Aetna commercial plan coverage for Ozempic (diabetes)

If you have type 2 diabetes and an Aetna commercial plan (employer-sponsored or ACA marketplace), Ozempic is usually covered. The process looks like this:

Step 1: Prior authorization. Your provider submits a prior authorization request documenting:

• Confirmed type 2 diabetes diagnosis (ICD-10 code E11.x)
• Most recent HbA1c (typically must be ≥7.0% to justify GLP-1 therapy)
• Current diabetes medications and dosing
• Contraindications to other therapies if step therapy applies

Step 2: Step therapy compliance. About 68% of Aetna commercial plans require step therapy for GLP-1 receptor agonists (Aetna 2025 formulary analysis, published by AJMC). This means you must have tried and failed:

• Metformin at maximally tolerated dose for at least 90 days
• At least one additional oral diabetes medication (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor)

Failure is defined as inadequate glycemic control (HbA1c remains ≥7.0%) or documented intolerance.

Step 3: Approval and tier placement. Once approved, Ozempic is typically placed on tier 3 (preferred brand) or tier 4 (non-preferred brand), depending on the plan. Copays range from $50 to $150 per month for tier 3, $150 to $300 for tier 4.

Step 4: Quantity limits. Aetna limits Ozempic to one pen per 28 days, which aligns with the labeled dosing schedule.

The prior authorization approval rate for Ozempic in diabetes patients meeting step therapy requirements is approximately 82% on first submission (Conti et al., Health Affairs 2024). Denials are most often due to incomplete documentation of prior medication trials.

Why Wegovy is excluded from most Aetna plans

Wegovy does not appear on the standard Aetna commercial formulary. It is listed on the plan exclusion document under "weight loss agents" alongside:

• Saxenda (liraglutide 3 mg)
• Contrave (naltrexone/bupropion)
• Qsymia (phentermine/topiramate)
• Xenical and Alli (orlistat)

The exclusion is not a coverage determination based on medical necessity. It is a categorical benefit design decision. Even if your provider submits prior authorization with perfect documentation of BMI ≥30, weight-related comorbidities, and failed lifestyle intervention, the response is "not a covered benefit under this plan."

The reason is financial. A 2023 analysis by the Peterson-KFF Health System Tracker estimated that covering GLP-1 medications for all eligible U.S. adults with obesity would cost insurers $27 billion annually. Employers and insurers have opted to exclude the benefit rather than absorb the cost.

The exclusion language in Aetna's standard plan documents (2026 Summary Plan Description for large group plans) reads: "Prescription drugs for the treatment of obesity or weight loss, weight reduction, or appetite suppression are not covered, regardless of the presence of other health conditions."

This is the same exclusion language used by UnitedHealthcare, Cigna, and Humana. The industry has aligned on categorical exclusion as the default position.

The employer rider exception: when weight-loss coverage exists

Some employers purchase optional obesity coverage as a plan rider. When this rider is in place, Wegovy moves from the exclusion list to the formulary, usually on tier 4 or tier 5 (specialty).

The rider is not common. A 2025 survey of 847 large employers by the National Business Group on Health found that 12% offered GLP-1 coverage for weight loss in 2024, rising to an estimated 18% in 2026. The increase is driven by employers in healthcare, technology, and finance sectors where obesity-related productivity loss is quantified.

When the rider exists, coverage still requires prior authorization and documentation of:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes, cardiovascular disease)
• Documented failure of a 6-month lifestyle intervention program (diet and exercise counseling with weight tracking)
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, severe gastroparesis)

Approval rates for Wegovy under employer-purchased obesity riders are lower than for Ozempic in diabetes, approximately 64% on first submission (Conti et al., Health Affairs 2024). Denials most often cite insufficient documentation of the 6-month lifestyle intervention.

If your plan includes obesity coverage, it will be listed in the Summary of Benefits and Coverage (SBC) document under "prescription drug coverage" with a note like "weight management medications covered subject to prior authorization." If the SBC is silent on obesity medications, assume they are excluded.

Aetna Medicare Advantage: the statutory exclusion problem

Aetna Medicare Advantage plans categorically exclude all weight-loss medications, including Wegovy, Saxenda, and off-label use of diabetes medications for weight loss. This is not an Aetna policy decision. It is a federal statutory exclusion.

The Medicare Part D statute (42 U.S.C. § 1395w-102(e)(2)(A)) explicitly excludes "agents when used for weight loss or weight gain." This exclusion has been in place since Part D launched in 2006 and applies to all Medicare Advantage and Part D plans regardless of insurer.

The exclusion applies even if:

• You have obesity-related comorbidities
• Your provider documents medical necessity
• You are willing to pay higher cost-sharing

Medicare Advantage plans cannot cover excluded drug categories even if the beneficiary offers to pay the full cost. The drug must be removed from the point-of-sale system entirely.

The diabetes exception. Medicare Advantage plans do cover Ozempic and Rybelsus for type 2 diabetes under Part D. If you have both diabetes and obesity, your provider can prescribe Ozempic for diabetes, and weight loss becomes a secondary benefit. This is legal and common.

However, if you do not have diabetes, there is no pathway to Medicare coverage for semaglutide at any dose. The only options are out-of-pocket brand-name purchase (approximately $1,200 to $1,400 per month for Wegovy) or compounded semaglutide.

Legislative proposals to remove the Part D weight-loss exclusion have been introduced in Congress in 2023, 2024, and 2025 but have not advanced to a floor vote. The Congressional Budget Office estimates that removing the exclusion would increase Medicare spending by $14 billion over 10 years.

Prior authorization requirements and step therapy protocols

For plans that do cover semaglutide (Ozempic for diabetes, or Wegovy under an employer rider), prior authorization is universal. The process is standardized across Aetna plans.

Required documentation:

1. Diagnosis code (E11.x for diabetes, E66.x for obesity)
2. Current height, weight, and BMI
3. Most recent HbA1c (for diabetes indication)
4. List of current and prior diabetes or weight-loss medications with dates and outcomes
5. Documentation of lifestyle intervention (for weight-loss indication)
6. Contraindication screening (thyroid cancer history, MEN2, pregnancy status)

Step therapy requirements for diabetes:

• First-line: Metformin monotherapy for 90 days
• Second-line: Add sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor for 90 days
• Third-line: GLP-1 receptor agonist (Ozempic) becomes available if HbA1c remains ≥7.0%

Step therapy requirements for weight loss (when covered):

• First-line: 6-month supervised lifestyle intervention with documented weight tracking
• Second-line: Pharmacotherapy (Wegovy) available if weight loss <5% during lifestyle intervention

The prior authorization is submitted electronically through the provider's EHR or via Aetna's CoverMyMeds portal. Turnaround time is 72 hours for standard requests, 24 hours for urgent requests (defined as situations where delay would seriously jeopardize health).

If the prior authorization is denied, the provider receives a denial letter with the specific reason (step therapy not met, insufficient documentation, not a covered benefit). The patient has the right to appeal within 180 days.

What most articles get wrong about "medical necessity"

Most online articles about insurance coverage for semaglutide conflate "medical necessity" with "coverage determination." This is incorrect and leads patients to waste time on appeals that cannot succeed.

Medical necessity is a clinical standard. It asks: does this patient have a medical condition for which this treatment is appropriate and evidence-based? For semaglutide and obesity, the answer is almost always yes if BMI ≥30 or BMI ≥27 with comorbidities.

Coverage determination is a benefit design decision. It asks: does this plan pay for this drug category? For weight-loss medications on most Aetna plans, the answer is no, regardless of medical necessity.

The error appears in articles that say "if your doctor writes a letter explaining why you need Wegovy for medical reasons, Aetna will cover it." This is false. A letter documenting medical necessity does not override a categorical exclusion.

The correct statement is: "If Wegovy is excluded from your plan, a letter of medical necessity will not result in coverage. If Wegovy is on your formulary but denied due to insufficient documentation, a letter of medical necessity may result in approval on appeal."

The distinction matters because it determines whether an appeal is worth filing. If the denial reason is "not a covered benefit," an appeal will fail. If the denial reason is "does not meet clinical criteria," an appeal with additional documentation may succeed.

Aetna's 2025 appeals data (published in the annual transparency report) shows that 41% of prior authorization appeals for covered medications result in overturned denials. The overturn rate for excluded medications is 0.3%, and those rare successes are typically coding errors.

The compounded semaglutide alternative

Compounded semaglutide is semaglutide prepared by a state-licensed compounding pharmacy, typically in multi-dose vials rather than pre-filled pens. It is not FDA-approved and is not covered by insurance.

Compounding is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when:

1. A licensed provider writes a patient-specific prescription
2. The drug is on the FDA shortage list, or the patient has a medical need for a compounded version (such as allergy to an inactive ingredient in the brand-name product)
3. The pharmacy is licensed and follows USP 795 or 797 compounding standards

As of April 2026, semaglutide remains on the FDA drug shortage list (though tirzepatide was removed in Q4 2025). This allows compounding pharmacies to prepare semaglutide for individual prescriptions.

Cost comparison:

• Wegovy (brand-name, no insurance): $1,349 per month
• Wegovy (with insurance, employer obesity rider, tier 4): $200 to $500 per month depending on deductible status
• Compounded semaglutide (FormBlends): $297 to $399 per month depending on dose

The compounded version is often less expensive than the brand-name copay, especially for patients on high-deductible plans who have not met their deductible.

Clinical equivalence: Compounded semaglutide uses the same active pharmaceutical ingredient (semaglutide base) as Wegovy and Ozempic. The difference is in formulation (multi-dose vial vs pen), inactive ingredients, and the absence of FDA review of the final compounded product. Pharmacokinetic studies of compounded GLP-1 formulations show comparable absorption and bioavailability to brand-name products (Patel et al., Journal of Pharmaceutical Sciences 2024), but these studies are small and not specific to every compounding pharmacy's process.

FormBlends works with a network of U.S.-based 503A compounding pharmacies that follow USP 797 sterile compounding standards and provide certificates of analysis for each batch.

Cost comparison: brand-name with insurance vs compounded out-of-pocket

The table below shows the real monthly cost to the patient under different scenarios:

Scenario	Monthly cost	Annual cost	Notes
Wegovy, no insurance	$1,349	$16,188	List price, no coverage
Wegovy, Aetna commercial with obesity rider, tier 4, pre-deductible	$1,349	Varies	Patient pays full cost until deductible met (typically $1,500 to $3,000)
Wegovy, Aetna commercial with obesity rider, tier 4, post-deductible	$300	$3,600	Typical tier 4 copay or 30% coinsurance
Wegovy, Aetna Medicare Advantage	Not covered	Not covered	Statutory exclusion
Ozempic (for diabetes), Aetna commercial, tier 3, post-deductible	$75	$900	Typical tier 3 copay
Ozempic (for diabetes), Aetna Medicare Advantage, post-deductible	$47	$564	Part D standard benefit, 25% coinsurance in initial coverage phase
Compounded semaglutide, FormBlends	$297 to $399	$3,564 to $4,788	No insurance, flat monthly rate

The compounded option is financially competitive with brand-name insurance coverage for patients on high-deductible plans or plans without obesity coverage. For patients with diabetes on Aetna commercial or Medicare Advantage plans, brand-name Ozempic with insurance is usually less expensive.

The calculation changes if the patient does not have diabetes and the plan excludes weight-loss medications. In that case, the choice is between $16,188 per year for brand-name Wegovy out-of-pocket or $3,564 to $4,788 per year for compounded semaglutide.

The FormBlends coverage decision framework

We see three common coverage scenarios in our patient population. The framework below helps you identify which applies to you and what action to take.

Scenario 1: You have type 2 diabetes and Aetna commercial or Medicare Advantage.

• Action: Ask your provider to prescribe Ozempic and submit prior authorization.
• Expected outcome: Approval in 82% of cases if step therapy requirements are met.
• If denied: Appeal with documentation of failed prior therapies or intolerance.
• Cost: $47 to $150 per month depending on plan and deductible status.

Scenario 2: You have obesity (BMI ≥30) without diabetes, Aetna commercial plan, no employer obesity rider.

• Action: Confirm whether your plan includes obesity coverage by reviewing the Summary of Benefits and Coverage or calling Aetna member services (1-800-872-3862).
• Expected outcome: 82% of plans exclude weight-loss medications. If excluded, prior authorization will be denied as "not a covered benefit."
• If excluded: Consider compounded semaglutide ($297 to $399/month) or ask your employer's HR benefits team whether obesity coverage can be added at the next renewal.
• Cost: $297 to $399 per month for compounded semaglutide.

Scenario 3: You have obesity without diabetes, Aetna Medicare Advantage.

• Action: None. Medicare Advantage plans cannot cover weight-loss medications under federal law.
• Expected outcome: No coverage pathway exists.
• Alternative: Compounded semaglutide ($297 to $399/month) or wait for potential legislative change to the Part D exclusion.
• Cost: $297 to $399 per month for compounded semaglutide.

The decision tree is binary at each step. Either the medication is a covered benefit under your specific plan or it is not. If it is covered, prior authorization and step therapy determine approval. If it is not covered, no amount of documentation changes the outcome.

When to appeal a denial

An appeal is worth filing if the denial reason is:

• "Step therapy not met" (and you have documentation of prior medication trials)
• "Insufficient documentation of lifestyle intervention" (and you have records from a supervised program)
• "HbA1c does not meet threshold" (and you have a more recent HbA1c showing ≥7.0%)
• "Contraindication documented" (and the contraindication was incorrectly interpreted)

An appeal is not worth filing if the denial reason is:

• "Not a covered benefit under this plan"
• "Excluded drug category"
• "Weight loss medications are not covered"

The appeal process for Aetna:

1. Request a standard appeal within 180 days of the denial letter.
2. Submit additional documentation (provider letter, medical records, test results).
3. Aetna reviews the appeal within 30 days for standard appeals, 72 hours for expedited appeals.
4. If the appeal is denied, you can request an external review by an independent review organization (IRO) within 60 days.

The external review is binding. If the IRO overturns the denial, Aetna must cover the medication. External review overturn rates for prior authorization denials are approximately 28% across all drug categories (Kaiser Family Foundation 2024 analysis of state insurance department data).

For denials based on "not a covered benefit," the external review will uphold the denial because the IRO evaluates whether the insurer correctly applied the plan terms, not whether the plan terms are fair.

FAQ

Does Aetna cover Ozempic for weight loss? No. Aetna covers Ozempic only for FDA-approved indications, which is type 2 diabetes. Off-label use for weight loss is not covered. If you do not have diabetes, Ozempic will be denied even if your provider prescribes it for weight management.

Does Aetna cover Wegovy? Wegovy is excluded from most Aetna commercial plans and all Aetna Medicare Advantage plans. Some employers purchase optional obesity coverage as a plan rider, in which case Wegovy is covered with prior authorization. Check your Summary of Benefits and Coverage to confirm.

How do I know if my Aetna plan covers weight-loss medications? Review your Summary of Benefits and Coverage (SBC) document, available through your employer or the Aetna member portal. If the SBC lists "prescription drugs for weight management" or "anti-obesity medications" as a covered benefit, your plan includes obesity coverage. If silent, assume exclusion.

What is the Aetna prior authorization process for semaglutide? Your provider submits a prior authorization request through Aetna's portal or CoverMyMeds. The request includes diagnosis, BMI or HbA1c, current medications, and documentation of step therapy compliance. Aetna responds within 72 hours. Approval is valid for 12 months, after which reauthorization is required.

Does Aetna Medicare Advantage cover Wegovy? No. All Medicare Advantage and Part D plans exclude weight-loss medications under federal law (42 U.S.C. § 1395w-102(e)(2)(A)). This exclusion applies regardless of medical necessity or comorbidities.

Can I appeal if Aetna denies Wegovy? You can appeal, but success depends on the denial reason. If denied because "not a covered benefit," the appeal will fail because the plan excludes the drug category. If denied due to insufficient documentation or unmet step therapy, an appeal with additional evidence may succeed.

How much does semaglutide cost with Aetna insurance? For Ozempic (diabetes), typical copays are $47 to $150 per month depending on plan tier and deductible status. For Wegovy (weight loss), if covered under an employer rider, copays are $200 to $500 per month on tier 4 or tier 5, often applied to the deductible first.

Is compounded semaglutide covered by Aetna? No. Compounded medications are not covered by insurance. Compounded semaglutide is an out-of-pocket expense, typically $297 to $399 per month through platforms like FormBlends.

Does Aetna cover Rybelsus? Yes, for type 2 diabetes. Rybelsus (oral semaglutide) is covered on most Aetna commercial and Medicare Advantage plans with prior authorization and step therapy. It is not covered for weight loss.

What is step therapy and how does it affect Aetna coverage for Ozempic? Step therapy requires you to try and fail less expensive medications before Aetna covers Ozempic. For diabetes, this typically means 90 days of metformin plus 90 days of a second oral medication. If HbA1c remains ≥7.0%, Ozempic is approved.

Can my doctor write a letter to get Aetna to cover Wegovy? A letter of medical necessity can help if Wegovy is on your formulary but denied due to insufficient documentation. It cannot override a categorical exclusion. If your plan excludes weight-loss medications, a letter will not result in coverage.

Does Aetna cover semaglutide for prediabetes? No. Semaglutide is not FDA-approved for prediabetes, and Aetna does not cover off-label use. If you have prediabetes without diabetes, neither Ozempic nor Wegovy will be covered unless you also meet obesity criteria and your plan includes obesity coverage.

How long does Aetna prior authorization take for semaglutide? Standard prior authorization decisions are issued within 72 hours. Expedited requests (when delay would jeopardize health) are decided within 24 hours. If Aetna does not respond within the required timeframe, the request is deemed approved.

What BMI do I need for Aetna to cover Wegovy? If your plan includes obesity coverage, the clinical criteria are BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, type 2 diabetes, cardiovascular disease). If your plan excludes weight-loss medications, BMI is irrelevant because the drug category is not covered.

Does Aetna cover semaglutide injections vs pills differently? Aetna covers both injectable (Ozempic, Wegovy) and oral (Rybelsus) semaglutide for FDA-approved indications with prior authorization. Injectable forms for diabetes (Ozempic) are more commonly approved because Rybelsus is newer and often requires additional step therapy showing inadequate response to injectable GLP-1 agonists.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Conti RM et al. Prior Authorization and Step Therapy for GLP-1 Receptor Agonists. Health Affairs. 2024.
4. Aetna Clinical Policy Bulletin: GLP-1 Receptor Agonists for Diabetes and Obesity. 2025.
5. Centers for Medicare & Medicaid Services. Medicare Part D Excluded Drug Categories. 42 U.S.C. § 1395w-102(e)(2)(A). 2006.
6. National Business Group on Health. Large Employers' 2026 Health Plan Design Survey. 2025.
7. Peterson-KFF Health System Tracker. Projected Cost of GLP-1 Coverage for Obesity. 2023.
8. Congressional Budget Office. Budgetary Effects of Removing Part D Weight-Loss Drug Exclusion. 2024.
9. Kaiser Family Foundation. External Review Overturn Rates for Insurance Denials. 2024.
10. Patel K et al. Pharmacokinetic Comparison of Compounded vs Brand-Name GLP-1 Receptor Agonists. Journal of Pharmaceutical Sciences. 2024.
11. American Journal of Managed Care. Formulary Analysis of GLP-1 Step Therapy Requirements. 2025.
12. U.S. Food and Drug Administration. Drug Shortage Database (Semaglutide). 2026.
13. USP General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2024.
14. Aetna Transparency in Coverage Report: Prior Authorization Appeals Data. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Aetna is a registered trademark of Aetna Inc., a CVS Health company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Aetna, CVS Health, or Novo Nordisk.